Comparative Effectiveness of Personalized Pharmacogenomic Guided Antidepressant Therapy Versus Standard Care in Major Depressive Disorder
Keywords:
Major Depressive Disorder, Pharmacogenomics, Antidepressants, Personalized Medicine, Treatment Outcomes, Standard CareAbstract
Major Depressive Disorder (MDD) is a leading cause of disability worldwide, with significant variability in treatment response. Pharmacogenomic-guided therapy (PGT) has emerged as a promising approach to personalize antidepressant treatment, potentially improving outcomes compared to standard care (SC). This study compares the effectiveness of PGT versus SC in MDD patients, focusing on remission rates, symptom improvement, and tolerability. A systematic review of literature and analysis of clinical data were conducted. Results indicate that PGT significantly enhances remission rates and reduces adverse effects, suggesting its potential as a superior treatment strategy. This paper highlights the clinical implications of integrating pharmacogenomics into MDD management.
References
[1] Bousman, C. A., et al. “Pharmacogenomics in Psychiatry: Clinical Implications.” Journal of Clinical Medicine, 2019.
[2] Greden, J. F., et al. “Impact of Pharmacogenomics on Antidepressant Treatment Outcomes.” American Journal of Psychiatry, 2018.
[3] Hicks, J. K., et al. “Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes.” Clinical Pharmacology & Therapeutics, 2017.
[4] Rosenblat, J. D., et al. “Challenges in Implementing Pharmacogenomic Testing in Depression Treatment.” Journal of Affective Disorders, 2020.
[5] Perlis, R. H., et al. “Pharmacogenomic Testing and Depressive Symptom Remission: A Randomized Clinical Trial.” JAMA Psychiatry, 2016.
[6] Bradley, P., et al. “Pharmacogenomics and Antidepressant Response: A Meta-Analysis of Genome-Wide Association Studies.” Molecular Psychiatry, 2018.
[7] Fabbri, C., et al. “The Role of Genetic Variants in Serotonin Transporter and Receptors in Antidepressant Response.” Pharmacogenomics Journal, 2019.
[8] Altar, C. A., et al. “Clinical Validity of Combinatorial Pharmacogenomic Testing for Antidepressant Outcomes.” Journal of Clinical Psychiatry, 2015.
[9] Winner, J. G., et al. “Pharmacogenomic Testing in Major Depressive Disorder: A Review of Clinical Effectiveness and Guidelines.” CADTH Rapid Response Reports, 2013.
[10] Singh, A. B., et al. “Pharmacogenomics in Depression Treatment: Current Evidence and Future Directions.” CNS Drugs, 2017.
